Research programme: CNS disorder therapeutics - Rodin Therapeutics

Drug Profile

Research programme: CNS disorder therapeutics - Rodin Therapeutics

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Rodin Therapeutics
  • Class Small molecules
  • Mechanism of Action HDAC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Alzheimer's disease
  • No development reported CNS disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for research development in CNS-disorders in USA
  • 17 Nov 2017 Rodin Therapeutics plans clinical development for Parkinson’s disease
  • 06 Jan 2016 Rodin Therapeutics and Biogen enter into a research and development collaboration for the development of therapeutics for the treatment of central nervous system diseases
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top